Colorectal cancer
Conditions
Interventions
Observation group:None
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The patient is pathologically and radiologically diagnosed with metastatic colorectal malignant tumor; 2. The molecular pathological result of the primary tumor is MSS, MSI-L, or pMMR, with RAS and BRAF being either wild-type or mutant; 3. Having previously received chemotherapy based on fluoropyrimidines, oxaliplatin, irinotecan, etc., and having received or being unsuitable for anti-VEGF or anti-EGFR targeted therapy; 4. Sufficient bone marrow, liver, and kidney function reserve, with an ECOG performance status score of 0-1 at the initial treatment; 5. No concurrent second primary malignant tumor; 6. Aged over 18 years old, regardless of gender.
Exclusion criteria
Exclusion criteria: 1. Patients with severe combined organ dysfunction of the heart, liver, kidneys, or other organs; 2. Patients with a history of allergies to the drugs used in the study protocol (such as regorafenib, fruquintinib, PD-1 inhibitors, etc.); 3. Pregnant or lactating women; 4. Patients with mental illness or cognitive impairment who are unable to cooperate with follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival after treatment;Overall survival period of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease control rate;All adverse events;Incidence of grade >=3 adverse events;Quality of Life Score;Eastern Cooperative Oncology Group Performance Status; | — |
Countries
China
Contacts
Public ContactCheng Zhiqiang
China-Japan Friendship Hospital
Outcome results
None listed